Title : First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations.

Pub. Date : 2022 Mar

PMID : 35076999






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations. osimertinib epidermal growth factor receptor Homo sapiens
2 Osimertinib is the standard treatment for non-small cell lung cancer (NSCLC) with an active epidermal growth factor receptor (EGFR) mutation and a T790M mutation-present in cases of acquired resistance. osimertinib epidermal growth factor receptor Homo sapiens
3 Osimertinib is the standard treatment for non-small cell lung cancer (NSCLC) with an active epidermal growth factor receptor (EGFR) mutation and a T790M mutation-present in cases of acquired resistance. osimertinib epidermal growth factor receptor Homo sapiens
4 However, there have been no reports on the efficacy of osimertinib in patients with EGFR G719S and de novo T790M mutations. osimertinib epidermal growth factor receptor Homo sapiens